Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 11 to 20 of 2245 total matches.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019 (Issue 1583)
-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA ...
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.
Oral Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2000 (Issue 1078)
known to decrease acne.
SOME ORAL CONTRACEPTIVES
Drug Estrogen (µg)
1
Progestin (mg)
2
Cost
3 ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Comparison Chart: SGLT2 Inhibitors (online only)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
2 (SGLT2) INHIBITORS RENAL DOSAGE ADJUSTMENTS CANAGLIFLOZIN eGFR 30 to ...
View the Comparison Chart: SGLT2 Inhibitors
Yasmin -- an Oral Contraceptive With a New Progestin
The Medical Letter on Drugs and Therapeutics • Jun 24, 2002 (Issue 1133)
-years of use,
which is similar to rates with other combination OCs. A 1-year study found 1 pregnancy ...
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
In Brief: Calcium and Vitamin D to Prevent Osteoporotic Fractures
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
/day) will benefit from
taking supplements.1
Table 1. Calcium Content of Some Foods1
Serving Calcium ...
The US Preventive Services Task Force (USPSTF) has issued a Draft Recommendation Statement saying, in effect, that community-dwelling women and men should not take calcium and vitamin D supplements for primary prevention of osteoporotic fractures because the evidence that they are helpful is insufficient and they increase the risk of kidney stones. The Medical Letter has said previously that there is no evidence that patients with an adequate intake of calcium (1000-1200 mg/day) and vitamin D (600-800 IU/day) will benefit from taking supplements.11. Drugs for postmenopausal osteoporosis. Treat...
Liraglutide (Victoza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 05, 2010 (Issue 1335)
) for Type 2
Diabetes
Liraglutide (Victoza – Novo Nordisk), a glucagon-like
peptide-1 (GLP-1) receptor ...
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous
injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
-experienced
patients. Mavyret is also approved for treatmentnaive
patients.
HCV GENOTYPES — HCV genotype 1 ...
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of the
six major HCV genotypes in patients without cirrhosis
or with compensated cirrhosis. Both are approved for
use in treatment-experienced patients. Mavyret is also
approved for treatment-naive patients.
COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
oxygenation (ECMO).1
Baricitinib was previously available for this indication
under an Emergency Use ...
The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for use in children 2-17 years old hospitalized with COVID-19 who require oxygen support.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
that are chemically similar to endogenous hormones
such as estradiol and progesterone.1 FDA-approved
formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
pembrolizumab (Keytruda –
Merck), a human programmed death receptor-1 (PD-1)
blocking antibody, for treatment ...
The FDA has approved pembrolizumab (Keytruda –
Merck), a human programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable or
metastatic melanoma that has progressed following
treatment with ipilimumab (Yervoy) and, if the patient
is BRAF V600 mutation positive, a BRAF inhibitor. It
is the fi rst PD-1 inhibitor to be marketed in the US.
Nivolumab, another PD-1 inhibitor, is available in
Japan. Pembrolizumab was previously known as
lambrolizumab.